2. Immunology/Inflammation
  3. PD-1/PD-L1
  4. Toripalimab

Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma.

For research use only. We do not sell to patients.

CAS No. : 1924598-82-2

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Toripalimab Featured Recommendations:

Toripalimab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma[1].

Isotype

Human IgG4 kappa
Recommend Isotype Controls
Species

Humanized
In Vitro

Toripalimab specifically binds to PD-1 (EC50 21 nmol/L) and inhibits binding of PD-1 to PD-L1 [IC50 3.0 nmol/L (≈ 0.5 μg/mL)] and PD-L2 (IC50 3.1 nmol/L) in 293F cells transfected with PD-1 plasmids[2].
Toripalimab (0.01–10 μg/mL) dose-dependently promotes human T-cell proliferation[2].
Toripalimab promotes interferon-γ and TNF-α secretion in activated human peripheral blood mononuclear cell (PBMC)-derived T cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Toripalimab Related Antibodies
In Vivo

Toripalimab (0.3-10 mg/kg; i.p.; twice a week, total 6 times) exhibits substantial tumor suppressive efficacy in a dose-dependent manner[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A genetically modified mouse strain with human PD-1 knocked in (were subcutaneously inoculated with 1 × 106 MC38 cells)[3]
Dosage: 0.3, 1, 3, 10 mg/kg
Administration: Intraperitoneal injection (i.p.); twice a week, total 6 times
Result: Inhibition of tumor growth was observed in a dose-dependent manner with substantial antitumor efficacy in 1, 3, and 10 mg/kg treatment groups. Decreased significantly at the end of the observation period (day 23)
Clinical Trial
Molecular Weight

147300.00

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Toripalimab]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 kappa
Biological Activity
  • Immobilized PD-1 Protein, Human (143a.a, HEK293, His, HY-7396) can bind Toripalimab. The EC50 for this effect is 7.504 ng/mL.
Purity & Documentation

Purity: 99.30%

SDS (251 KB)

COA (231 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Toripalimab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Toripalimab1924598-82-2PD-1/PD-L1PD-1/Programmed death-ligand 1the first domestic anti-tumor PD-1 antibodymelanomalung cancerdigestive tract tumorshepatobiliary and pancreatic tumorsneuroendocrine neoplasmsnasopharyngeal carcinomaurothelial carcinomaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Toripalimab
Cat. No.:
HY-P9978
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.